ROCKAWAY, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a peer-reviewed study in Frontiers in Neurology demonstrating the effectiveness of gammaCore® non-invasive vagus nerve stimulation (nVNS) in reducing persistent symptoms associated with mild traumatic brain injury (mTBI). “The CDC reports approximately 2.5 million emergency department visits each year in the United States for ...

ROCKAWAY, N.J., Sept. 29, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that gammaCore™ Sapphire (nVNS) has been included in a long-term reimbursement policy launched by the National Institute for Health and Disability Insurance (RIZIV / INAMI) in Belgium. Effective October 1, 2025, the policy provides coverage for gammaCore Sapphire to treat patients with cluster headaches. This coverage is based on strong clinical ...

Core Insights - electroCore, Inc. announced that its Truvaga™ Plus handheld vagus nerve stimulation device was named the "Best Relaxation Gadget" in Esquire's 2025 Sleep Awards, highlighting its effectiveness in promoting relaxation and restorative sleep [1][2] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through non-invasive bioelectronic technologies. Its leading products include gammaCore for chronic pain and Truvaga for general wellness [3][5] Product Details - Truvaga Plus is designed to activate the vagus nerve quickly and gently, promoting a balanced nervous system for improved calmness, clarity, and sleep. It is intended for general health and wellness and is not a medical device [5][6] - The device offers a drug-free alternative for relaxation and sleep, with sessions lasting just two minutes, making it convenient for daily use [8] Recognition and Validation - The recognition from Esquire serves as validation for Truvaga Plus, reinforcing consumer confidence in its effectiveness as a proven, non-drug solution for sleep and relaxation challenges [2][3]

Company Leadership Changes - Peter Cuneo has departed from the Board of Directors of electroCore, Inc., with Thomas J. Errico, MD, elected as the new Chairman of the Board effective September 2, 2025 [1][2] - Cuneo will continue to serve as a strategic advisor to the company [1] - CEO Dan Goldberger expressed gratitude for Cuneo's contributions since 2020, highlighting his role in the company's turnaround [2] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through non-invasive bioelectronic technologies [3] - The company's leading products include gammaCore, a non-invasive vagus nerve stimulation device, and Quell neurostimulator, both aimed at treating chronic pain syndromes [3] - Additionally, electroCore markets handheld products like Truvaga and TAC-STIM, which utilize bioelectronic technologies for general wellness and human performance [3]

Core Insights - electroCore, Inc. has partnered with former NFL player Greg Buttle to promote its Truvaga™ Plus device, which is designed for vagus nerve stimulation to enhance relaxation, clarity, and sleep quality [1][4] - Truvaga Plus is a handheld device that utilizes bioelectronic technology to stimulate the vagus nerve, helping users transition from stress to a balanced state [3][8] - The partnership will include radio spots and digital campaigns aimed at raising awareness about stress management and the benefits of Truvaga Plus [4] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through non-invasive technologies [6] - The company offers products like gammaCore and Quell, which treat chronic pain, alongside Truvaga and TAC-STIM for general wellness [6] - Truvaga Plus is backed by over 20 years of research in bioelectronic medicine and is intended for general health and wellness purposes [5][8]

Core Insights - electroCore, Inc. has appointed Elena Bonfiglioli to its Board of Directors effective September 2, 2025, following the retirement of Peter Cuneo [1] - Ms. Bonfiglioli brings over two decades of experience in the healthcare sector, currently serving as Microsoft's Global Business Leader for Healthcare, Pharma Life Sciences, and International clinical applications [2] - She has been recognized as one of the top 50 AI Innovators and has held various leadership roles in healthcare organizations, emphasizing the use of data and AI to enhance health outcomes [2][3] Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through non-invasive bioelectronic technologies [4] - The company's leading products include gammaCore, a non-invasive vagus nerve stimulation device, and Quell neurostimulator, both aimed at treating chronic pain syndromes [4] - Additionally, electroCore markets handheld products like Truvaga and TAC-STIM, which utilize bioelectronic technologies for general wellness and human performance [4]

Company Overview - electroCore, Inc. is a commercial-stage bioelectronic technology company focused on improving health and quality of life through innovative non-invasive bioelectronic technologies [3] - The company's leading prescription products include gammaCore, a non-invasive vagus nerve stimulation (nVNS) device, and Quell neurostimulator, both aimed at treating chronic pain syndromes through non-invasive neuromodulation technology [3] - Additionally, electroCore offers handheld and personal use products such as Truvaga and TAC-STIM nVNS, which utilize bioelectronic technologies to promote general wellness and human performance [3] Upcoming Events - Management of electroCore will participate in the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025, at the Lotte New York Palace Hotel [1] - One-on-one meetings will be hosted throughout the day for interested investors [1] Investor Relations - Investors wishing to request a meeting can contact their sales representative at H.C. Wainwright or reach out to electroCore Investor Relations via email at ecor@fnkir.com [2]

Core Insights - electroCore, Inc. has appointed Kelly Benning as the Senior Vice President of Truvaga, effective July 21, 2025, bringing nearly 30 years of experience in digital health and consumer wellness [1][3] - Ms. Benning emphasizes the shift in the wellness market towards personalized, consumer-centric solutions, aiming to innovate and refine technology to empower individuals in managing their well-being [2][3] - The company focuses on building a movement around science-backed wellness solutions and plans to leverage strategic partnerships for greater accessibility to its consumer devices [2][3] Company Overview - electroCore is a commercial-stage bioelectronic technology company dedicated to improving health and quality of life through non-invasive bioelectronic technologies [5] - The company's leading products include gammaCore, a non-invasive vagus nerve stimulation device, and Quell neurostimulator, both targeting chronic pain syndromes [5] - electroCore also markets Truvaga™, a handheld device aimed at promoting general wellness and human performance [5] Leadership Background - Kelly Benning has a proven track record in bringing digital health products to market, including the first FDA-cleared watch for blood pressure monitoring [2][3] - Her previous roles include executive positions at LiveMetric, IBM Watson Health, and other healthcare enterprises, showcasing her extensive experience in the industry [3] - The CEO of electroCore, Dan Goldberger, expressed confidence in Ms. Benning's ability to expand the company's direct-to-consumer strategy [4]

分组1 - electroCore, Inc. reported a quarterly loss of $0.35 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.32, but an improvement from a loss of $0.38 per share a year ago, resulting in an earnings surprise of -9.38% [1] - The company posted revenues of $7.38 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 0.83%, and showing an increase from $6.14 million in the same quarter last year [2] - electroCore has surpassed consensus revenue estimates two times over the last four quarters, while it has only exceeded consensus EPS estimates once during the same period [2] 分组2 - The stock has underperformed significantly, losing about 57.7% since the beginning of the year, compared to a 7.1% gain in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.27 on revenues of $7.81 million, and for the current fiscal year, it is -$1.19 on revenues of $30.72 million [7] - The Zacks Industry Rank for Medical - Drugs is currently in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Financial Data and Key Metrics Changes - The company reported record revenue of $7.4 million for Q2 2025, representing a 20% increase year-over-year and a 10% sequential increase [7][19] - Gross margins remained strong at 87%, slightly up from 86% in the previous year [7][20] - GAAP net loss was $3.7 million, or a loss of $0.44 per share, compared to a net loss of $2.7 million, or $0.38 per share, in the previous year [21][22] - Cash balance as of June 30, 2025, was approximately $7.4 million, down from $12.2 million at the end of 2024 [22][23] Business Line Data and Key Metrics Changes - Revenue from the VA hospital system grew 12% sequentially, reaching $5.3 million in Q2 2025 [8][19] - Direct-to-consumer brand TRUVEGA posted $1 million in sales for Q2, a 74% year-over-year growth but a sequential decline [10][19] - The U.S. prescription channel recorded revenue of $394,000, down 17% year-over-year [13][19] Market Data and Key Metrics Changes - Revenue from outside the U.S. was $465,000 for the quarter, down 9% from the same period last year [14][19] - The total addressable market within the VA channel is significant, with estimates of 600,000 patients treated for headaches [8][9] Company Strategy and Development Direction - The company is transitioning from a single product focus to a broader bioelectronic technology company, with plans to invest in growth and long-term value creation [5][12] - The integration of the recently acquired Neurometrics has been completed ahead of schedule, and the company is focusing on expanding its product offerings [6][25] - The company plans to increase marketing and promotional investments in the TRUVEGA platform to drive growth in 2026 and beyond [11][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of the VA channel and the direct-to-consumer market, despite delays in profitability due to increased spending [25][29] - The company expects to need $11.5 million to $12 million in quarterly revenue to achieve cash positivity, significantly higher than the current revenue levels [18][19] - Management highlighted the importance of gross profit margins, which could lead to improved operating margins once sufficient revenue is generated [19][25] Other Important Information - The company entered into a term debt facility with Avenue Capital, providing approximately $7.2 million in additional net cash [14][23] - The company is facing patent infringement issues with a competitor, which has led to legal expenses [11][36] Q&A Session Summary Question: Insights into TRUVEGA revenue composition - The $500 TRUVEGA Plus accounts for about 80% of revenue in the category, while the $350 version lags behind [35] Question: Legal actions regarding patent infringement - Cross complaints have been filed in federal court, but no further comments were made beyond public filings [36] Question: New product expectations - The prescription Quell Fibromyalgia product line is now operational, expected to generate material revenue in the latter half of the year [38][39] Question: Annualized marketing spend increase - Marketing spend is expected to increase by 5% to 6% in line with revenue growth [42][43] Question: Decision to ramp up spending and delay profitability - The decision was influenced by restructuring the sales force and positive trends in direct-to-consumer business [48][49] Question: Contribution of Amazon sales - The company is still resolving issues related to order fulfillment from Amazon [48] Question: Return on advertising spend - The media efficiency ratio was 2.0, indicating $2 of revenue generated for every $1 spent on advertising [57] Question: Integration with Apple Health - The integration allows access to a larger biohacker ecosystem, with potential use cases being explored [59]